Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 Followed by Temozolomide in Metastatic Melanoma
NCT01124734Phase 2Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2010
- Primary completion
- Jul 2017
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin, temozolomide in melanoma, sponsored by Penn State Health Milton S. Hershey Medical Center. Started May 2010; status: completed.
02
Drugs
aldesleukintemozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01124734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01124734.